GSK, Sanofi and CSL will also make additional bulk vaccine ingredients matched to circulating strains of bird flu, Boucher said. Australia's CSL recently secured a contract worth $121.4 million to increase the U.S. government's stockpile for bird flu vaccines to 40 million doses.

Sanofi (NASDAQ:SNY), and CSL (OTCQX:CSLLY) to expand the production of bird flu vaccines amid an ongoing outbreak among poultry and livestock that has led to fears of a potential human-to-human transmission of the virus.

The U.S. government collaborates with GSK, Sanofi, and CSL to enhance bird flu vaccine production. This initiative aims to increase vaccine readiness to 10 million doses by early 2025 amid rising H5 cases.

CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the country’s supply of bird flu vaccines. | CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.

GSK, Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, Bloomberg News reported on Friday. The move comes as a multi-state outbreak among livestock and poultry has caused several human infections,

Sanofi (SNY), and CSL (CSLLY) win $72M U.S. contract to expand bird flu vaccine production amid fears of human transmission. Read more here.